RxDoctor Payments Data

Jeffrey Courville, MD

Family Medicine · Tucson, AZNPI 1801123948

Payments from drug & device makers

$2,406in general payments, 2019–2025

Across 21 payments — averaging $114.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$736
  • Abbott$453
  • GSK$244
  • AbbVie$225
  • Ironwood Pharmaceuticals, Inc$137
  • Bard Peripheral Vascular, Inc.$136
  • plus $474 from 4 others

What the payments were for

  • Food & beverage$2,406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,406 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$44,467
Medicare patients
164
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$73,348
EliquisApixaban38$51,970
JardianceEmpagliflozin28$44,587
FarxigaDapagliflozin Propanediol36$41,058
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$31,939
TrulicityDulaglutide15$14,339
LantusInsulin Glargine,hum.Rec.Anlog26$5,500
Omeprazole186$5,067
Gabapentin182$4,864
SymbicortBudesonide/Formoterol Fumarate11$4,151
Albuterol Sulfate HfaAlbuterol Sulfate162$3,975
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,537
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$3,165
Atorvastatin Calcium448$3,016
Rosuvastatin Calcium302$2,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$122$73,34847 claims
AstraZenecaFarxiga, Symbicort$736$45,20947 claims
GSKTrelegy Ellipta$244$31,93926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →